Whether mirikizumab is already on the market and its market trends

As of2025, Milikizumab (Mirikizumab) has not been approved for marketing in mainland China, and patients need to purchase the drug through overseas channels. In the Hong Kong market, the original drug price of militizumab is approximately RMB 10,000 (300mg/15mla box). Since it has not yet been covered by medical insurance, patients need to bear all costs themselves, which imposes a heavy financial burden.

In the international market, militizumab has been approved by many countries and regions. In 2023, the EU and the United States respectively approved militizumab for the treatment of moderately to severely active ulcerative colitis (UC). In 2024, militizumab also received approval for the treatment of moderately to severely active Crohn's disease. In addition, militizumab has been approved in 44 countries and regions, including Japan, Canada, etc.

Milizumab has shown promising efficacy in clinical trials. In the LUCENT-1 and LUCENT-2 studies, militizumab significantly improved clinical response rates and quality of life scores in patients with ulcerative colitis. In the VIVID-1 study, militizumab also showed significant efficacy in patients with moderately to severely active Crohn's disease.

Looking forward to the future, the prospect of Milizumab being launched in China deserves attention. In 2024, militizumab completed a single-dose safety and pharmacokinetics study on healthy volunteers in China. As clinical data accumulates and the regulatory approval process advances, militizumab is expected to be approved by the China National Medical Products Administration within the next few years. Once it is launched and included in medical insurance, patients' medication burden is expected to be significantly reduced.

Reference materials:https://www.drugs.com/